ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
22
02
2019
revised:
10
09
2019
accepted:
12
11
2019
pubmed:
21
11
2019
medline:
12
1
2021
entrez:
21
11
2019
Statut:
ppublish
Résumé
The ERK pathway is critical in oncogenesis; aberrations in components of this pathway are common in approximately 30% of human cancers. ERK1/2 (ERK) regulates cell proliferation, differentiation, and survival and is the terminal node of the pathway. BRAF- and MEK-targeted therapies are effective in BRAF V600E/K metastatic melanoma and lung cancers; however, responses are short-lived due to emergence of resistance. Reactivation of ERK signaling is central to the mechanisms of acquired resistance. Therefore, ERK inhibition provides an opportunity to overcome resistance and leads to improved efficacy. In addition,
Identifiants
pubmed: 31744895
pii: 1535-7163.MCT-19-0183
doi: 10.1158/1535-7163.MCT-19-0183
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT02857270']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-336Informations de copyright
©2019 American Association for Cancer Research.